J
Jerome A. Yesavage
Researcher at Stanford University
Publications - 446
Citations - 43320
Jerome A. Yesavage is an academic researcher from Stanford University. The author has contributed to research in topics: Cognition & Dementia. The author has an hindex of 73, co-authored 423 publications receiving 39527 citations. Previous affiliations of Jerome A. Yesavage include United States Department of Veterans Affairs & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Single case study. Possible organophosphate-induced parkinsonism.
TL;DR: The course of this patient raises the possibility that agricultural workers may be at risk for the late development of parkinsonism, and a balance hypothesis between cholinergic and dopaminergic neurotransmission in the striatum is discussed.
Journal ArticleDOI
α2 Macroglobulin and the risk of Alzheimer’s disease
Richard C. Dodel,Yansheng Du,K.R. Bales,Feng Gao,B. Eastwood,Bradley S. Glazier,Reinhilde Zimmer,Barbara Cordell,Ann Marie Hake,Rebecca M. Evans,Dolores Gallagher-Thompson,Larry W. Thompson,Jared R. Tinklenberg,Adolf Pfefferbaum,Edith V. Sullivan,Jerome A. Yesavage,L. Altstiel,T. Gasser,Martin R. Farlow,Greer M. Murphy,Steven M. Paul +20 more
TL;DR: The data support an association between the A2M gene and AD, less pronounced in this cohort than in the previously reported sample of sibpairs, and the expected association between AD and APOE-ε4.
Journal ArticleDOI
Inpatient evaluation of aggression in psychiatric patients.
TL;DR: The authors rated violent and violence-related behavior of patients on a psychiatric intensive care unit, and found that despite the restricted environment such behavior was manifested to a considerable degree.
Journal ArticleDOI
Development of Aphasia, Apraxia, and Agnosia and Decline in Alzheimer's Disease
TL;DR: Alzheimer's disease patients who developed aphasia or apraxia declined more rapidly than those patients who did not develop either sign, suggesting the presence of subtypes of Alzheimer's disease in which accelerated decline is associated with the early appearance of certain neurological signs.
Journal ArticleDOI
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer’s Dementia: Evidence From the CitAD Study
Anne K. Leonpacher,Matthew E. Peters,Lea T. Drye,Kelly M. Makino,Jeffery Newell,D.P. Devanand,Constantine Frangakis,Cynthia A. Munro,Jacobo Mintzer,Bruce G. Pollock,Paul B. Rosenberg,Lon S. Schneider,David M. Shade,Daniel Weintraub,Jerome A. Yesavage,Constantine G. Lyketsos,Anton P. Porsteinsson +16 more
TL;DR: While dosage constraints must be considered because of citalopram's adverse effect profile, this agent's overall therapeutic effects in patients with Alzheimer's disease and agitation, in addition to efficacy for agitation/aggression, included reductions in the frequency of irritability, anxiety, and delusions.